Loughlin Gerard, Romaniega Tomás Datino, Garcia-Fernandez Javier, Calvo David, Salgado Ricardo, Alonso Andres, Li Xin, Arenal Angel, González-Torrecilla Esteban, Atienza Felipe, Fernández-Avilés Francisco
Department of Cardiology, Instituto de Investigación Sanitaria del Hospital General Universitario Gregorio Marañón, Hospital General Universitario Gregorio Marañón, C/Dr. Esquerdo 46, 28007, Madrid, Spain.
Hospital Universitario Asistencial, Burgos, Spain.
J Interv Card Electrophysiol. 2016 Mar;45(2):149-58. doi: 10.1007/s10840-015-0098-x. Epub 2016 Jan 6.
Many centers perform catheter ablation for atrial fibrillation (AF) with periprocedural interruption of oral vitamin K antagonists. In this scenario, the optimal post-procedural anticoagulation strategy is still under debate. We sought to compare the incidence of major complications associated with post-procedural use of low molecular weight heparin (LMWH) versus unfractioned heparin (UFH) as a bridge to reinitiation of oral anticoagulation after an AF ablation procedure.
We retrospectively reviewed medical history data of all patients undergoing catheter ablation for AF at three Spanish referral centers between January 2009 and January 2014. A total of 702 patients were included in the analysis. We compared the incidence of major complications (a combination of major bleeding and thromboembolic events) between patients receiving UFH (291) and those receiving LMWH (411) after the procedure.
The overall incidence of major complications was 4.1%, including five thromboembolic events (0.7%) and 24 major bleeding events (3.4%), with no significant differences in patients treated with LMWH vs. UFH (2.9 vs. 4.1%; P = NS). The presence of peripheral vascular disease emerged as the only independent predictor of major complications (adjusted odds ratio (OR) 9.1; confidence interval (CI) 95% 1.7-49.3; P < 0.01).
Immediate post-procedural bridging with UFH or with LMWH are equally safe strategies in patients undergoing catheter ablation for AF in whom oral anticoagulation is interrupted for the procedure. Due to its greater simplicity of use, LMWH may be the preferred option. The presence of peripheral vascular disease is a potent predictor of major post-procedural complications.
许多中心在心房颤动(AF)导管消融术中会在围手术期中断口服维生素K拮抗剂。在这种情况下,术后最佳抗凝策略仍存在争议。我们旨在比较低分子量肝素(LMWH)与普通肝素(UFH)在AF消融术后作为重新开始口服抗凝的桥梁使用时,相关主要并发症的发生率。
我们回顾性分析了2009年1月至2014年1月在西班牙三个转诊中心接受AF导管消融术的所有患者的病史数据。共有702例患者纳入分析。我们比较了术后接受UFH(291例)和接受LMWH(411例)的患者中主要并发症(大出血和血栓栓塞事件的组合)的发生率。
主要并发症的总发生率为4.1%,包括5例血栓栓塞事件(0.7%)和24例大出血事件(3.4%),接受LMWH与UFH治疗的患者之间无显著差异(2.9%对4.1%;P = 无统计学意义)。外周血管疾病的存在是主要并发症的唯一独立预测因素(校正比值比(OR)9.1;95%置信区间(CI)1.7 - 49.3;P < 0.01)。
对于因手术而中断口服抗凝的AF导管消融患者,术后立即使用UFH或LMWH进行桥接是同样安全的策略。由于使用更简便,LMWH可能是首选。外周血管疾病的存在是术后主要并发症的有力预测因素。